Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid
- PMID: 31763806
- DOI: 10.1021/acsami.9b17749
Cell-Selective Messenger RNA Delivery and CRISPR/Cas9 Genome Editing by Modulating the Interface of Phenylboronic Acid-Derived Lipid Nanoparticles and Cellular Surface Sialic Acid
Abstract
Messenger RNA (mRNA) represents an emerging class of nucleic acid therapeutics for genome editing and genetic disease treatment. Delivering exogenous mRNA selectively to cells, however, remains a main challenge to broaden the biomedical application of mRNA and develop targeted gene therapy. Herein, we report cell-selective mRNA delivery and CRISPR/Cas9 genome editing by modulating the interface of phenylboronic acid (PBA) derived lipid nanoparticles (NPs) and cellular surface sialic acid (SA). We design a cationic lipid featuring a PBA group, PBA-BADP, to self-assemble with mRNA into nanoparticles via electrostatic interactions. Importantly, these nanoparticles present free PBA groups on their surface, showing an enhanced cellular uptake by SA-overexpressing cancer cells via the interfacial PBA/SA interaction. It is shown that PBA-BADP/mRNA NPs transfection results in 300 times higher luciferase reporter gene expression in cancer cells than that in noncancer cells. Moreover, we demonstrate that the delivery of tumor suppressor p53 mRNA using PBA-BADP selectively prohibits cancer cell growth, while PBA-BADP/Cas9 mRNA NPs delivery knocks out gene expression of HeLa cancer cells in a much higher efficiency than noncancer cells. We believe these findings could further extend the modulation of PBA and cellular SA interface to advance mRNA delivery and genome editing for new gene therapy.
Keywords: CRISPR/Cas9 genome editing; cell-selective delivery; lipid nanoparticles; mRNA delivery; sialic acid.
Similar articles
-
Fast and Efficient CRISPR/Cas9 Genome Editing In Vivo Enabled by Bioreducible Lipid and Messenger RNA Nanoparticles.Adv Mater. 2019 Aug;31(33):e1902575. doi: 10.1002/adma.201902575. Epub 2019 Jun 19. Adv Mater. 2019. PMID: 31215123 Free PMC article.
-
Development of ionizable lipid nanoparticles and a lyophilized formulation for potent CRISPR-Cas9 delivery and genome editing.Int J Pharm. 2024 Mar 5;652:123845. doi: 10.1016/j.ijpharm.2024.123845. Epub 2024 Jan 22. Int J Pharm. 2024. PMID: 38266942
-
Intracellular Delivery of mRNA for Cell-Selective CRISPR/Cas9 Genome Editing using Lipid Nanoparticles.Chembiochem. 2023 May 2;24(9):e202200801. doi: 10.1002/cbic.202200801. Epub 2023 Mar 30. Chembiochem. 2023. PMID: 36780174 Review.
-
Integrating Combinatorial Lipid Nanoparticle and Chemically Modified Protein for Intracellular Delivery and Genome Editing.Acc Chem Res. 2019 Mar 19;52(3):665-675. doi: 10.1021/acs.accounts.8b00493. Epub 2018 Dec 26. Acc Chem Res. 2019. PMID: 30586281 Free PMC article.
-
Nanoparticle-Based Delivery of CRISPR/Cas9 Genome-Editing Therapeutics.AAPS J. 2018 Oct 10;20(6):108. doi: 10.1208/s12248-018-0267-9. AAPS J. 2018. PMID: 30306365 Free PMC article. Review.
Cited by
-
CRISPR/Cas9 systems: Delivery technologies and biomedical applications.Asian J Pharm Sci. 2023 Nov;18(6):100854. doi: 10.1016/j.ajps.2023.100854. Epub 2023 Oct 21. Asian J Pharm Sci. 2023. PMID: 38089835 Free PMC article. Review.
-
Biomaterials-mediated CRISPR/Cas9 delivery: recent challenges and opportunities in gene therapy.Front Chem. 2023 Sep 28;11:1259435. doi: 10.3389/fchem.2023.1259435. eCollection 2023. Front Chem. 2023. PMID: 37841202 Free PMC article. Review.
-
Lipid-based nanoparticles as drug delivery systems for cancer immunotherapy.MedComm (2020). 2023 Aug 7;4(4):e339. doi: 10.1002/mco2.339. eCollection 2023 Aug. MedComm (2020). 2023. PMID: 37560754 Free PMC article. Review.
-
Intelligent nanotherapeutic strategies for the delivery of CRISPR system.Acta Pharm Sin B. 2023 Jun;13(6):2510-2543. doi: 10.1016/j.apsb.2022.12.013. Epub 2022 Dec 22. Acta Pharm Sin B. 2023. PMID: 37425051 Free PMC article. Review.
-
The use of plant-derived exosome-like nanoparticles as a delivery system of CRISPR/Cas9-based therapeutics for editing long non-coding RNAs in cancer colon cells.Front Oncol. 2023 Jun 14;13:1194350. doi: 10.3389/fonc.2023.1194350. eCollection 2023. Front Oncol. 2023. PMID: 37388221 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
